Neuren Pharmaceuticals Limited (ASX:NEU) Insider Acquires A$97,450.00 in Stock

Neuren Pharmaceuticals Limited (ASX:NEUGet Free Report) insider Joseph(Joe) Basile bought 5,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was acquired at an average cost of A$19.49 ($12.91) per share, for a total transaction of A$97,450.00 ($64,536.42).

Neuren Pharmaceuticals Stock Performance

Neuren Pharmaceuticals Company Profile

(Get Free Report)

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.

Featured Articles

Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.